168 related articles for article (PubMed ID: 26559905)
1. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
[TBL] [Abstract][Full Text] [Related]
2. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
Strati P; Parikh SA; Chaffee KG; Achenbach SJ; Slager SL; Call TG; Ding W; Jelinek DF; Hanson CA; Kay NE; Shanafelt TD
Br J Haematol; 2017 Jul; 178(1):99-105. PubMed ID: 28386906
[TBL] [Abstract][Full Text] [Related]
3. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.
Gattei V; Bulian P; Del Principe MI; Zucchetto A; Maurillo L; Buccisano F; Bomben R; Dal-Bo M; Luciano F; Rossi FM; Degan M; Amadori S; Del Poeta G
Blood; 2008 Jan; 111(2):865-73. PubMed ID: 17959854
[TBL] [Abstract][Full Text] [Related]
4. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.
Rossi D; Zucchetto A; Rossi FM; Capello D; Cerri M; Deambrogi C; Cresta S; Rasi S; De Paoli L; Bodoni CL; Bulian P; Del Poeta G; Ladetto M; Gattei V; Gaidano G
Haematologica; 2008 Oct; 93(10):1575-9. PubMed ID: 18641015
[TBL] [Abstract][Full Text] [Related]
5. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.
Shanafelt TD; Geyer SM; Bone ND; Tschumper RC; Witzig TE; Nowakowski GS; Zent CS; Call TG; Laplant B; Dewald GW; Jelinek DF; Kay NE
Br J Haematol; 2008 Mar; 140(5):537-46. PubMed ID: 18275431
[TBL] [Abstract][Full Text] [Related]
6. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
7. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
8. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups.
MacIntyre DA; Jiménez B; Lewintre EJ; Martín CR; Schäfer H; Ballesteros CG; Mayans JR; Spraul M; García-Conde J; Pineda-Lucena A
Leukemia; 2010 Apr; 24(4):788-97. PubMed ID: 20090781
[TBL] [Abstract][Full Text] [Related]
9. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
10. Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance.
López C; Delgado J; Costa D; Villamor N; Navarro A; Cazorla M; Gómez C; Arias A; Muñoz C; Cabezas S; Baumann T; Rozman M; Aymerich M; Colomer D; Pereira A; Cobo F; López-Guillermo A; Campo E; Carrió A
Genes Chromosomes Cancer; 2013 Oct; 52(10):920-7. PubMed ID: 23893575
[TBL] [Abstract][Full Text] [Related]
11. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
12. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
Majid A; Lin TT; Best G; Fishlock K; Hewamana S; Pratt G; Yallop D; Buggins AG; Wagner S; Kennedy BJ; Miall F; Hills R; Devereux S; Oscier DG; Dyer MJ; Fegan C; Pepper C
Leuk Res; 2011 Jun; 35(6):750-6. PubMed ID: 21093051
[TBL] [Abstract][Full Text] [Related]
13. Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia.
Zou ZJ; Fan L; Wang L; Zhang R; Zhang LN; Yang S; Li JY; Xu W
Cancer Biomark; 2012; 12(4):169-76. PubMed ID: 23568007
[TBL] [Abstract][Full Text] [Related]
14. Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
Chauzeix J; Laforêt MP; Deveza M; Crowther L; Marcellaud E; Derouault P; Lia AS; Boyer F; Bargues N; Olombel G; Jaccard A; Feuillard J; Gachard N; Rizzo D
Cancer Med; 2018 Jun; 7(6):2621-2628. PubMed ID: 29745034
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
Kern W; Bacher U; Haferlach C; Dicker F; Alpermann T; Schnittger S; Haferlach T
Br J Haematol; 2012 Apr; 157(1):86-96. PubMed ID: 22224978
[TBL] [Abstract][Full Text] [Related]
16. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia.
Nückel H; Switala M; Collins CH; Sellmann L; Grosse-Wilde H; Dührsen U; Rebmann V
Clin Immunol; 2009 Jun; 131(3):472-80. PubMed ID: 19318232
[TBL] [Abstract][Full Text] [Related]
17. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia.
Stamatopoulos B; Meuleman N; Haibe-Kains B; Duvillier H; Massy M; Martiat P; Bron D; Lagneaux L
Clin Chem; 2007 Oct; 53(10):1757-66. PubMed ID: 17702857
[TBL] [Abstract][Full Text] [Related]
18. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
Bomben R; Dal Bo M; Capello D; Forconi F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Zucchetto A; Bertoni F; Rossi FM; Bulian P; Cattarossi I; Ilariucci F; Sozzi E; Spina V; Zucca E; Degan M; Lauria F; Del Poeta G; Efremov DG; Marasca R; Gaidano G; Gattei V
Br J Haematol; 2009 Feb; 144(4):492-506. PubMed ID: 19036101
[TBL] [Abstract][Full Text] [Related]
19. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
[TBL] [Abstract][Full Text] [Related]
20. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.
Zanotti R; Ambrosetti A; Lestani M; Ghia P; Pattaro C; Remo A; Zanetti F; Stella S; Perbellini O; Prato G; Guida G; Caligaris-Cappio F; Menestrina F; Pizzolo G; Chilosi M
Leukemia; 2007 Jan; 21(1):102-9. PubMed ID: 17082778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
